Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HDACi, HMA combo improves survival for older AML patients

Publish date:: March 13, 2019

Key clinical point: Pracinostat plus azacitidine induced more complete remissions (CRs) than azacitidine alone in older patients with AML.

Major finding: The primary endpoint – CR, CR with incomplete recovery of blood counts, or morphologic leukemia-free state – occurred in 26 of 50 patients.

Study details: Phase 2 trial in 50 patients older than 65 years with newly diagnosed AML.

Disclosures: The study was supported by research funding from MEI Pharma. Dr. Garcia-Manero reported having no disclosures. Multiple coauthors reported financial relationships with MEI and others. One coauthor is an MEI employee.

Citation:

Garcia-Manero G et al. Blood Adv. 2019 Feb 26;3(4):508-18.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,